Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9409003 | 0.89 | TP53 (0.58) | GAAMAPTATMSMN1; SMN2RAB9A | |
| SCHEMBL13989319 | 0.84 | GAA (0.73) | GAAMAPTATMSMN1; SMN2RAB9A | |
| SCHEMBL145468 | 0.84 | TP53 (0.67) | MAPTSMN1; SMN2RAB9AALDH1A1HPGD | |
| SCHEMBL4133285 | 0.81 | ALDH1A1 (0.58) | SMN1; SMN2RAB9AALDH1A1HPGDCA12 | |
| SCHEMBL196368 | 0.81 | MEN1 (0.42) | GAAMAPTRAB9AALDH1A1HPGD | |
| Water SCHEMBL27398863 | 0.81 | GAA (0.81) | GAAMAPTATMSMN1; SMN2RAB9A | |
| SCHEMBL10962729 | 0.80 | HPGD (0.62) | GAAMAPTSMN1; SMN2RAB9AHPGD | |
| SCHEMBL8118546 | 0.80 | CA1 (0.56) | GAAMAPTALDH1A1HPGDCA1 | |
| SCHEMBL4629132 | 0.80 | GAA (0.49) | GAAMAPTATMSMN1; SMN2RAB9A | |
| SCHEMBL6342401 | 0.80 | ALDH1A1 (0.59) | SMN1; SMN2RAB9AALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3723744-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| CN-111511363-A | C5aR inhibitors for the treatment of chemotherapy-induced iatrogenic pain | 多姆皮制药公司 | 2020-08-07 | — | — | CN | claimed |
| CN-1200114-A | Quinoline derivatives as GNRH antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-11-25 | — | — | CN | claimed |
| EP-0876349-A1 | QUINOLINE DERIVATIVES AS GNRH ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 1998-11-11 | — | — | EP | claimed |
| US-5807869-A | Quinoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-15 | — | — | US | claimed |
| WO-1997014682-A1 | QUINOLINE DERIVATIVES AS GNRH ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-24 | — | — | WO | claimed |
| EP-0387201-B1 | Mixture of dyestuffs and their use | CIBA GEIGY AG (CH) | 1994-02-02 | — | — | EP | claimed |
| US-5131919-A | Trichromic dyeing or printing | CIBA-GEIGY CORPORATION (US) | 1992-07-21 | — | — | US | claimed |
| EP-0387201-A1 | Mixture of dyestuffs and their use | CIBA-GEIGY AG (CH) | 1990-09-12 | — | — | EP | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| US-4262851-A | HIGH SPEED MILLING WITHOUT SURFACTANTS | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | GAA 4565/4885MAPT 3127/4885ATM 1287/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885ATM 3654/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | GAA 139/4885MAPT 4669/4885ATM 3654/4885 |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | GAA 4834/4885MAPT 4697/4885ATM 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.